(19S)-19-ethyl-19-hydroxy-10-{2-[(propan-2-yl)amino]ethyl}-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione hydrochloride

• ChemBase编号: 161176
• 分子式: C25H28ClN3O4
• 平均质量: 469.96052
• 单一同位素质量: 469.17683407
• SMILES: c1ccc2c(c1)c(c1c(n2)c2n(C1)c(=O)c1c(c2)[C@@](C(=O)OC1)(O)CC)CCNC(C)C.Cl
• Canonical SMILES: CC[C@@]1(O)C(=O)OCc2c1cc1c3nc4ccccc4c(c3Cn1c2=O)CCNC(C)C.Cl
• InChI: InChI=1S/C25H27N3O4.ClH/c1-4-25(31)19-11-21-22-17(12-28(21)23(29)18(19)13-32-24(25)30)15(9-10-26-14(2)3)16-7-5-6-8-20(16)27-22;/h5-8,11,14,26,31H,4,9-10,12-13H2,1-3H3;1H/t25-;/m0./s1
• InChIKey: SJKBXKKZBKCHET-UQIIZPHYSA-N

名称和登记号

名称

• IUPAC标准名: (19S)-19-ethyl-19-hydroxy-10-{2-[(propan-2-yl)amino]ethyl}-17-oxa-3,13-diazapentacyclo[11.8.0.0^2,^1^1.0^4,^9.0^1^5,^2^0]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione hydrochloride
• IUPAC传统名: belotecan hydrochloride
• 别名: (4S)-4-Ethyl-4-hydroxy-11-[2-[(1-methylethyl)amino]ethyl]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione Hydrochloride; CKD 602; Belotecan Hydrochloride

登记号

• CAS号: 213819-48-8
• PubChem SID: 162255311
• PubChem CID: 6918340

理论计算性质

• Acid pKa: 11.723949
• 质子受体: 5
• 质子供体: 2
• LogD (pH = 5.5): -1.3931212
• LogD (pH = 7.4): -0.8674284
• Log P: 1.6911196
• 摩尔折射率: 121.6629 cm^3
• 极化性: 47.843155 Å^3
• 极化表面积: 91.76 Å^2
• 可自由旋转的化学键: 5
• 里宾斯基五规则: true

详细说明

Toronto Research Chemicals - B131300

A novel camptothecin-derivative anti-tumor agent. CKD-602-related toxicities induced by IV infusion administration have not yet been evaluated, although the drug is more widely used in clinical settings.

参考文献

• Hertzberg, R., et al.: J. Med. Chem., 32, 715 (1989)
• Hashimoto, H., et al.: Clin. Cancer Res., 1, 369 (19950, Dahut, W., et al.: J. Clin. Oncol., 14, 1236 (1989)